Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Rhea-AI Summary

Climb Bio (Nasdaq: CLYM) has announced its participation in William Blair's Transforming Autoimmune Diseases by Targeting CD19 event. The company will present and host investor meetings at this conference, which is scheduled for Wednesday, October 16, 2024, in New York, NY.

This event focuses on innovative approaches to treating autoimmune diseases, specifically targeting CD19. Climb Bio's involvement suggests their work aligns with this cutting-edge area of medical research. The conference provides an opportunity for Climb Bio to showcase their developments and engage with investors interested in advancements in autoimmune disease treatments.

News Market Reaction – CLYM

+1.18%

+1.18% Session move

In the trading session that priced this news, CLYM gained 1.18%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.

About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375

FAQ

When and where is Climb Bio (CLYM) presenting at the William Blair conference?

Climb Bio (CLYM) is presenting at William Blair's Transforming Autoimmune Diseases by Targeting CD19 event on Wednesday, October 16, 2024, in New York, NY.

What is the focus of the William Blair conference that Climb Bio (CLYM) is attending?

The conference focuses on transforming autoimmune diseases by targeting CD19, which is an area of research that Climb Bio is involved in.

Will Climb Bio (CLYM) be hosting investor meetings at the William Blair event?

Yes, Climb Bio (CLYM) has announced that they will be hosting investor meetings at the William Blair conference on October 16, 2024.

What does Climb Bio's (CLYM) participation in this conference suggest about their research focus?

Climb Bio's participation suggests that their research is aligned with innovative approaches to treating autoimmune diseases, particularly those involving CD19 targeting.